Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof

US7126001B2 · kind B2 · utility

Assignees

• Sloan Kettering Institute for Cancer Research · US
• The Trustees of Columbia University in the City of New York · US

Inventors

• Ronald Breslow · Englewood, US
• Sandro Belvedere · Verona, IT
• Leland Gershell · New York, US
• Thomas A. Miller · Fort Worth, US
• Paul A. Marks · Washington, US
• Victoria M. Richon · Wellesley, US
• Richard A. Rifkind · New York, US

Key dates

• Filing date: Oct 25, 2002
• Grant date: Oct 24, 2006
• Expiry date: Oct 25, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides the compound having the formula:wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.